412 related articles for article (PubMed ID: 16249975)
1. The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
Törüner M; Bektaş M; Cetinkaya H; Soykan I; Ozden A
Turk J Gastroenterol; 2004 Dec; 15(4):225-8. PubMed ID: 16249975
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
3. The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach.
Wang K; Lin HJ; Perng CL; Tseng GY; Yu KW; Chang FY; Lee SD
Hepatogastroenterology; 2004; 51(59):1540-3. PubMed ID: 15362796
[TBL] [Abstract][Full Text] [Related]
4. [Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].
Kanayama S
Nihon Rinsho; 1999 Jan; 57(1):153-6. PubMed ID: 10036954
[TBL] [Abstract][Full Text] [Related]
5. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
Miner PB; Allgood LD; Grender JM
Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225
[TBL] [Abstract][Full Text] [Related]
6. Effect of proton pomp inhibitor (PPI : Rabeprazole) on reflux esophagitis after endoscopic injection sclerotherapy (EIS), a randomized control study (24 hour-pH monitoring).
Akahoshi T; Kawanaka H; Tomikawa M; Saeki H; Uchiyama H; Ikeda T; Shirabe K; Hashizume M; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):483-9. PubMed ID: 24693675
[TBL] [Abstract][Full Text] [Related]
7. Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
Javid G; Zargar SA; U-Saif R; Khan BA; Yatoo GN; Shah AH; Gulzar GM; Sodhi JS; Khan MA
J Gastroenterol Hepatol; 2009 Jul; 24(7):1236-43. PubMed ID: 19682194
[TBL] [Abstract][Full Text] [Related]
8. Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules.
Ono S; Kato M; Ono Y; Imai A; Yoshida T; Shimizu Y; Asaka M
J Gastroenterol Hepatol; 2009 Apr; 24(4):639-45. PubMed ID: 19032447
[TBL] [Abstract][Full Text] [Related]
9. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Sugimoto M; Furuta T; Shirai N; Nakamura A; Kajimura M; Hishida A; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2005 Apr; 77(4):302-11. PubMed ID: 15903128
[TBL] [Abstract][Full Text] [Related]
10. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
Gerson LB; Shetler K; Triadafilopoulos G
Dig Liver Dis; 2005 Sep; 37(9):651-8. PubMed ID: 15919250
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
Huang JQ; Hunt RH
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
[TBL] [Abstract][Full Text] [Related]
12. [Effect of H2-blockers and proton pump inhibitors on intragastric acidity and intraesophageal pH in patients with gastroesophageal reflux disease].
Ivanov AN; Iakovenko EP; Iakovenko AV
Eksp Klin Gastroenterol; 2004; (4):16-20, 107. PubMed ID: 15568661
[TBL] [Abstract][Full Text] [Related]
13. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Farley A; Wruble LD; Humphries TJ
Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
[TBL] [Abstract][Full Text] [Related]
14. [Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons].
Holtmann G; Layer P; Goebell H
Z Gastroenterol; 1996 May; 34(5):267-72. PubMed ID: 8686357
[TBL] [Abstract][Full Text] [Related]
15. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Ramdani A; Mignon M; Samoyeau R
Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
[TBL] [Abstract][Full Text] [Related]
16. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
Xue S; Katz PO; Banerjee P; Tutuian R; Castell DO
Aliment Pharmacol Ther; 2001 Sep; 15(9):1351-6. PubMed ID: 11552905
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effects of anti-secretory drugs on intragastric acidity: is combined therapy with a proton pump inhibitor and an H2 receptor antagonist effective as initial treatment?
Inamori M; Togawa J; Chiguchi G; Abe Y; Kikuchi T; Muramatsu K; Kawamura H; Kobayashi N; Kirikoshi H; Shimamura T; Sakaguchi T; Takamura T; Ueno N; Nakajima A
J Gastroenterol; 2005 Feb; 40(2):213-4. PubMed ID: 15770408
[No Abstract] [Full Text] [Related]
18. The influence of feeding on gastric acid suppression in Helicobacter pylori-positive patients treated with a proton pump inhibitor or an H2-receptor antagonist after bleeding from a gastric ulcer.
Ozawa T; Yoshikawa N; Tomita T; Akita Y; Mitamura K
J Gastroenterol; 2003; 38(9):844-8. PubMed ID: 14564629
[TBL] [Abstract][Full Text] [Related]
19. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
Gardner JD; Sloan S; Robinson M; Miner PB
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1381-6. PubMed ID: 15606401
[TBL] [Abstract][Full Text] [Related]
20. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens.
Adachi K; Komazawa Y; Fujishiro H; Mihara T; Ono M; Yuki M; Kawamura A; Karim Rumi MA; Amano Y; Kinoshita Y
J Gastroenterol; 2003; 38(9):830-5. PubMed ID: 14564627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
